248 related articles for article (PubMed ID: 15017211)
1. An analysis of men with clinically localized prostate cancer who deferred definitive therapy.
Patel MI; DeConcini DT; Lopez-Corona E; Ohori M; Wheeler T; Scardino PT
J Urol; 2004 Apr; 171(4):1520-4. PubMed ID: 15017211
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
3. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
4. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
Gelet A; Chapelon JY; Bouvier R; Pangaud C; Lasne Y
J Urol; 1999 Jan; 161(1):156-62. PubMed ID: 10037389
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
6. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
7. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up].
Isorna Martínez de la Riva S; Belón López-Tomasety J; Marrero Domínguez R; Alvarez Cruz E; Santamaría Blanco P
Arch Esp Urol; 2004 Sep; 57(7):679-92. PubMed ID: 15536949
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
10. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
11. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
Phillips JJ; Hall MC; Lee WR; Clark PE
Urol Oncol; 2007; 25(3):196-200. PubMed ID: 17483015
[TBL] [Abstract][Full Text] [Related]
12. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
Carter HB; Walsh PC; Landis P; Epstein JI
J Urol; 2002 Mar; 167(3):1231-4. PubMed ID: 11832703
[TBL] [Abstract][Full Text] [Related]
13. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.
Al Otaibi M; Ross P; Fahmy N; Jeyaganth S; Trottier H; Sircar K; Bégin LR; Souhami L; Kassouf W; Aprikian A; Tanguay S
Cancer; 2008 Jul; 113(2):286-92. PubMed ID: 18484590
[TBL] [Abstract][Full Text] [Related]
14. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
18. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
19. Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?
Graefen M; Walz J; Chun KH; Schlomm T; Haese A; Huland H
Eur Urol; 2005 Jun; 47(6):756-60. PubMed ID: 15925069
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
